Chris Miller, PhD, is the Director of Regulatory Affairs Clinical and Nonclinical Strategy at Pacira BioSciences. He completed his PhD in Epidemiology at the University of Pennsylvania under the mentorship of Dr. John Farrar, with dissertation research supported by the FDA focusing on the design and analysis of acute pain clinical trials. His doctoral work addressed methodological challenges in pain research, including establishing minimum clinically important differences in pain intensity, developing a more patient-centered efficacy endpoint for multi-dose clinical trials, and creating a reference-based multiple imputation approach to minimize bias introduced by rescue pain medication. Prior to his doctoral training, Chris served as Scientific Executive Consultant at 3D Communications for over ten years, where he led preparations for more than 30 FDA Advisory Committee meetings, with particular expertise in pain therapeutics. He has also served as a Biostatistics Subject Matter Expert for the Gates Foundation. Chris earned his MS in Biostatistics from the University of Minnesota. In his role at Pacira, Chris applies his methodological expertise to the development of non-opioid pain therapeutics, providing strategic guidance on clinical trial design and regulatory submissions.
Wednesday, December 17, 2025
2:00 pm
Causal Inference Methods for Treatment Effect Heterogeneity in Trials and Observational Studies
Thomas Riley is a postdoctoral fellow in Rheumatology at Penn Medicine and the Hospital of the University of Pennsylvania. He went to the Perelman School of Medicine at the University of Pennsylvania for medical school, and completed his internal medicine residency, chief residency, and clinical rheumatology fellowship at the Hospital of the University of Pennsylvania. His research applies pharmacoepidemiology and statistical genetics methods to understand how the the genetics of autoimmune disease influence treatment response, with a focus on rheumatoid arthritis.